Neurological manifestations due to dengue virus infection in children: clinical follow-up

Pathog Glob Health. 2021 Oct-Dec;115(7-8):476-482. doi: 10.1080/20477724.2021.1942680. Epub 2021 Jul 5.

Abstract

The aim was to assess neurological complications in children with an invasive neurological disease by dengue virus (DENV) and the time to resolve symptoms after hospital discharge. A prospective study was conducted at a referral hospital for infectious diseases in Brazil between March 2014 and July 2019. All children hospitalized with neurologic manifestations and DENV RNA detected by real-time reverse transcription-polymerase chain reaction (RT-qPCR) in cerebrospinal fluid (CSF) were followed up until complete resolution of neurological complications. On average, they were followed up for 16 months. Among 56 DENV-positive children, 39% had some neurologic complications after hospital discharge and found that 19.6% were discharged with anticonvulsants due to seizures, 10.7% developed motor complications (e.g. muscle weakness, paresis, ataxia, and walking disability), 5.4% had headaches, and 14.3% had sleep disorders. Among the 56 children, only three had a clinical diagnosis of dengue because the symptoms are nonspecific and 35% showed no change in cerebrospinal fluid (CSF). The average time to resolve complications was 5.9 months (ranging from 1 m to 32 m). These results should alert physicians to the difficulties of a clinical diagnosis of an infection that causes neurological complications after discharge in a significant number of children. RT-qPCR's etiological diagnosis of DENV infection enabled better clinical follow-up for early intervention in children with neurological complications.

Keywords: Dengue virus; children; encephalitis; meningitis; myelitis; neurologic complication.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Dengue Virus*
  • Dengue* / complications
  • Dengue* / diagnosis
  • Follow-Up Studies
  • Humans
  • Immunoglobulin M
  • Prospective Studies

Substances

  • Immunoglobulin M

Grants and funding

This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico [CNPq - 440911/2015 and 2058/2016], Departamento de Ciência e Tecnologia do Ministério da Saúde do Brasil (DECIT) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) finance code 001 and Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG). EGK is a fellow from CNPq and FAPEMIG.